Safety of endoscopy after recent bevacizumab use in metastatic colorectal cancer.
1/5 보강
[BACKGROUND AND AIMS] Bevacizumab improves metastatic colorectal cancer (mCRC) survival but increases risks including GI perforation.
- 표본수 (n) 396
- p-value P = .006
- p-value P = .001
APA
Sood A, Herman N, Hung CK (2025). Safety of endoscopy after recent bevacizumab use in metastatic colorectal cancer.. Gastrointestinal endoscopy. https://doi.org/10.1016/j.gie.2025.11.024
MLA
Sood A, et al.. "Safety of endoscopy after recent bevacizumab use in metastatic colorectal cancer.." Gastrointestinal endoscopy, 2025.
PMID
41274356 ↗
Abstract 한글 요약
[BACKGROUND AND AIMS] Bevacizumab improves metastatic colorectal cancer (mCRC) survival but increases risks including GI perforation. This study compared 30-day postendoscopy (EGD/colonoscopy) perforation and bleeding risks between mCRC patients receiving recent (≤1 month) bevacizumab versus other active chemotherapy.
[METHODS] TriNetX, a multinational federated electronic health network database, was used to create and analyze 1:1 propensity score-matched cohorts of patients who underwent endoscopy for either diagnostic purposes (n = 396 total postmatch) or therapeutic purposes (n = 1306) as well as combined (n = 2100). Time-to-event analysis on 30-day perforation risk and 30-day postprocedural bleeding was conducted using Kaplan-Meier analysis on matched cohorts as well as adjusted Cox proportional hazards models on unmatched cohorts for sensitivity analysis.
[RESULTS] Baseline covariates were balanced post matching. No significant difference in 30-day perforation risk was found (Combined hazard ratio [HR] 0.93, P = .791; Diagnostic HR 2.33, P = .143; Therapeutic HR 0.96, P = .925). Bevacizumab was associated with a significantly higher 30-day postprocedural bleeding risk in the Combined (matched HR 1.28, P = .006) and Therapeutic (matched HR 1.45, P = .001; adjusted HR 1.46, P < .001) analyses but not in the Diagnostic subgroup (matched HR 1.03, P = .894; adjusted HR 0.98, P = .921).
[CONCLUSIONS] Recent bevacizumab exposure was not associated with increased 30-day postendoscopy perforation risk compared with other active chemotherapy, but was associated with higher bleeding risk, primarily in therapeutic (specifically EGD) procedures.
[METHODS] TriNetX, a multinational federated electronic health network database, was used to create and analyze 1:1 propensity score-matched cohorts of patients who underwent endoscopy for either diagnostic purposes (n = 396 total postmatch) or therapeutic purposes (n = 1306) as well as combined (n = 2100). Time-to-event analysis on 30-day perforation risk and 30-day postprocedural bleeding was conducted using Kaplan-Meier analysis on matched cohorts as well as adjusted Cox proportional hazards models on unmatched cohorts for sensitivity analysis.
[RESULTS] Baseline covariates were balanced post matching. No significant difference in 30-day perforation risk was found (Combined hazard ratio [HR] 0.93, P = .791; Diagnostic HR 2.33, P = .143; Therapeutic HR 0.96, P = .925). Bevacizumab was associated with a significantly higher 30-day postprocedural bleeding risk in the Combined (matched HR 1.28, P = .006) and Therapeutic (matched HR 1.45, P = .001; adjusted HR 1.46, P < .001) analyses but not in the Diagnostic subgroup (matched HR 1.03, P = .894; adjusted HR 0.98, P = .921).
[CONCLUSIONS] Recent bevacizumab exposure was not associated with increased 30-day postendoscopy perforation risk compared with other active chemotherapy, but was associated with higher bleeding risk, primarily in therapeutic (specifically EGD) procedures.